Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Total Liabilities (2019 - 2026)

ADC Therapeutics has reported Total Liabilities over the past 8 years, most recently at $507.9 million for Q1 2026.

  • Quarterly results put Total Liabilities at $507.9 million for Q1 2026, down 0.57% from a year ago — trailing twelve months through Mar 2026 was $507.9 million (down 0.57% YoY), and the annual figure for FY2025 was $509.0 million, down 2.98%.
  • Total Liabilities reached $507.9 million in Q1 2026 per ADCT's latest filing, roughly flat from $509.0 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $527.9 million in Q3 2025 and bottomed at $380.4 million in Q4 2022.
  • Median Total Liabilities over the past 5 years was $507.9 million (2026), compared with a mean of $484.1 million.
  • Peak annual rise in Total Liabilities hit 156.03% in 2022, while the deepest fall reached 5.26% in 2022.
  • Over 5 years, Total Liabilities stood at $380.4 million in 2022, then skyrocketed by 32.24% to $503.0 million in 2023, then grew by 4.29% to $524.6 million in 2024, then decreased by 2.98% to $509.0 million in 2025, then decreased by 0.22% to $507.9 million in 2026.
  • Business Quant data shows Total Liabilities for ADCT at $507.9 million in Q1 2026, $509.0 million in Q4 2025, and $527.9 million in Q3 2025.